Nav: Home

Federal agencies need to prepare for greater quantity, range of biotechnology products

March 09, 2017

WASHINGTON -- A profusion of biotechnology products is expected over the next five to 10 years, and the number and diversity of new products has the potential to overwhelm the U.S. regulatory system, says a new report from the National Academies of Sciences, Engineering, and Medicine. The U.S. Environmental Protection Agency, the Food and Drug Administration, the U.S. Department of Agriculture, and other agencies involved in regulating biotechnology products should increase their scientific capabilities, tools, and expertise in key areas of expected growth, said the committee that conducted the study and wrote the report.

"The rate at which biotechnology products are introduced -- and the types of products -- are expected to significantly increase in the next five to 10 years, and federal agencies need to prepare for this growth," said committee chair Richard Murray, Thomas E. and Doris Everhart Professor of Control and Dynamical Systems and Bioengineering, California Institute of Technology. "We hope this report will support agency efforts to effectively evaluate these future products in ways that ensure public safety, protect the environment, build public confidence, and support innovation."

The U.S. biotechnology economy is growing rapidly, with the scale, scope, and complexity of products increasing. More types of organisms will likely be engineered, the report notes, and the kinds of traits introduced with biotechnology will also increase. Some future biotechnology products are likely to use genome-editing techniques such as CRISPR for familiar applications, such as modifying agricultural crops. Other future products are expected to be entirely new -- plants that can serve as sentinels of environmental contamination, for example, and collections of microorganisms that can produce chemical compounds efficiently. Engineered microbes, plants, and insects designed to live in the environment with little or no human management are likely to be more common. With few exceptions, products such as these have not yet been evaluated by the current regulatory system.

Current staffing levels, expertise, and resources available at EPA, FDA, USDA and other agencies may not be sufficient to address the expected scope and scale of future biotechnology products, the report says. It is critical that the agencies involved in regulation develop and maintain scientific capabilities, tools, and expertise in key evolving areas. Examples of such areas include understanding relationships between intended genetic changes and an organism's observable traits, the unintended effects of genetic changes on target and non-target organisms, predicting and monitoring ecosystem responses, and quantifying the economic and social costs and benefits of biotechnologies.

To respond to the expected increase and diversity of products, the agencies should develop risk-analysis approaches tailored to the familiarity of products and the complexity of their uses, the report says. For biotechnology products that are similar to products already in use, established risk-analysis methods can be applied or modified, and a more expedited process could be used. For products that have less-familiar characteristics or more complex risk pathways, new risk-analysis methods may need to be developed. Regulatory agencies should build their capacity to rapidly determine the type of risk-analysis approaches most appropriate for new products entering the regulatory system.

EPA, FDA, and USDA should identify products that could serve as pilot projects to develop new approaches to assess risks and benefits and to inform regulatory decisions, the report says. Pilot projects could also be used by the agencies to evaluate future products as they move from laboratory scale, to field- or prototype-scale, to full-scale operation.

One challenge regulators will face is finding jurisdiction under existing statutes to regulate the diverse range of anticipated biotech products, the report says. The current collection of statutes and regulations that provide the basis for agencies' oversight, known as the Coordinated Framework for Regulation of Biotechnology, appears to have considerable flexibility to cover a wide range of biotechnology products, but in some cases the agencies' jurisdiction has been defined in ways that could leave gaps or overlaps in regulatory oversight. At times, FDA, EPA, and USDA may need to make use of the flexibility under their statutes to minimize gaps in jurisdiction.

Even when statutes do allow agencies to regulate products, the current statutes may not adequately equip regulators with the tools to regulate the products effectively, the committee said. For example, the statutes may not empower regulators to require product sponsors to share in the burden of generating information about product safety, and may place the burden of proof on regulators to demonstrate that a product is unsafe before they can take action to protect the public. This implies that adequate federal support for research will be crucial to protect consumer and occupational safety and the environment.

Biotechnology products on the horizon are likely to generate substantial public debate, the report notes. Many members of society have concerns over the safety and ethics of various biotechnologies, while others see prospects for biotechnology addressing social or environmental problems. The U.S. regulatory system will need to achieve a balance among competing interests, risks, and benefits when considering how to manage development and use of new biotech products.

In addition, more research may be needed to develop methods for governance systems that integrate ethical, cultural, and social implications into risk assessments in ways that are meaningful. This may not be feasible or even justified for all new biotechnology products -- such as products with which there is already familiarity or products that will not be released into the environment. For example, genetically engineered organisms used in the research laboratory to develop new chemical synthesis methods are not likely to require the same level of public dialogue as products that have more uncertainty associated with them, such as organisms with gene drives, which enhance organisms' ability to pass certain genetic traits on to their offspring.

Overall, the federal government should develop a strategy that scans the horizon for new biotechnology products, identifying and prioritizing those products that are less familiar or that present a need for more complex risk analysis, the report says. The federal government should also work to establish appropriate federal funding levels for sustained, multiyear research to develop the necessary advances in regulatory science. To this end, the National Science Foundation, the U.S. Department of Defense, the U.S. Department of Energy, the National Institutes of Standards and Technology, and other agencies that fund biotechnology research should increase their investments in regulatory science.
The study was sponsored by the U.S. Environmental Protection Agency, Food and Drug Administration, and the U.S. Department of Agriculture. The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide independent, objective analysis and advice to the nation to solve complex problems and inform public policy decisions related to science, technology, and medicine. They operate under an 1863 congressional charter to the National Academy of Sciences, signed by President Lincoln. For more information, visit A roster follows.


Riya V. Anandwala, Media Officer
Joshua Blatt, Media Assistant
Office of News and Public Information
202-334-2138; e-mail
Follow us on Twitter at @theNASEM

Copies of Preparing for Future Products of Biotechnology are available from the National Academies Press on the Internet at or by calling 202-334-3313 or 1-800-624-6242. Reporters may obtain a copy from the Office of News and Public Information (contacts listed above).


Division on Earth and Life Studies

Board on Life Sciences, Board on Agriculture and Natural Resources, and Board on Chemical Sciences and Technology

Committee on Future Biotechnology Products and Opportunities to Enhance Capabilities of the Biotechnology Regulatory System

Richard M. Murray1 (chair)
Thomas E. and Doris Everhart Professor of Control and Dynamical Systems and Bioengineering
California Institute of Technology

Richard M. Amasino2
Department of Biochemistry
University of Wisconsin

Steven P. Bradbury
Departments of Natural Resource Ecology and Management and Entomology
Iowa State University

Barbara J. Evans
Department of Law, and
Center on Biotechnology
University of Houston

Steven L. Evans
Dow AgroSciences

Farren Isaacs
Assistant Professor
Department of Molecular, Cellular, and Developmental Biology
Yale University
New Haven, Conn.

Martha A. Krebs
Senior Scientist
College of Engineering
Pennsylvania State University

Jennifer Kuzma
Goodnight/NC GSK Foundation Distinguished Professor;
Co-Director and Professor
Genetic Engineering and Society Center
North Carolina State University

Mary E. Maxon Biosciences Area Principal Deputy
Lawrence Berkeley National Laboratory
Berkeley, Calif.

Raul F. Medina
Associate Professor
Department of Entomology
Texas A&M University
College Station

David Rejeski
Science, Technology, and Innovation Program
Environmental Law Institute
Washington, D.C.

Jeffrey D. Wolt
Professor of Agronomy and Toxicology
Biosafety Institute for Genetically Modified Agricultural Products
Iowa State University


Kara Laney
Study Director

1 Member, National Academy of Engineering

2 Member, National Academy of Sciences

National Academies of Sciences, Engineering, and Medicine

Related Biotechnology Articles:

Biotechnology to the rescue of Brussels sprouts
An international team has identified the genes that make these plants resistant to the pathogen that attacks crops belonging to the cabbage family all over the world.
UM professor co-authors report on the use of biotechnology in forests
University of Montana Professor Diana Six is one of 12 authors of a new report that addresses the potential for biotechnology to provide solutions for protecting forest trees from insect and pathogen outbreaks, which are increasing because of climate change and expanded global trade.
Faster genome evolution methods to transform yeast for industrial biotechnology
A research team led by Prof. DAI Junbiao at the Shenzhen Institutes of Advanced Technology (SIAT) of the Chinese Academy of Sciences, in collaboration with Prof.
New innovations in cell-free biotechnology
Professor Michael Jewett's new platform to conduct cell-free protein synthesis could lead to improved quality of manufactured protein therapeutics and biomaterials.
Silk 'micrococoons' could be used in biotechnology and medicine
Microscopic versions of the cocoons spun by silkworms have been manufactured by a team of researchers.
The end of biotechnology as we know it
More than 400 attendees from five continents discussed trends and improvements in biotechnology at the European Summit of Industrial Biotechnology (ESIB) in Graz/Austria and talked many topics like a dehumanized research process.
Biotechnology: A growing field in the developing world
A detailed new report surveys a broad cross-section of biotechnology work across developing countries, revealing steady growth in fields tied to human well-being worldwide.
China releases first report on biotechnology in developing countries
The first report on biotechnology in developing countries revealing an overall picture of their biotechnology growth and competitiveness was released on Nov.
Exclusive: Biotechnology leaders surveyed about impact of Trump presidency
The day following the election of Donald J. Trump as President, a survey of leaders in biotechnology in the United States, conducted by Genetic Engineering & Biotechnology News showed that Trump's presidency will negatively impact NIH research funding as well as STEM education; a plurality said it will also spark a 'brain drain' as foreign-born researchers educated in American universities will be more likely to leave.
Novel 'repair system' discovered in algae may yield new tools for biotechnology
The algae C. reinhardtii uses a novel system for releasing an interrupting sequence from a protein -- a technique that may be useful for protein purification.
More Biotechnology News and Biotechnology Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Teaching For Better Humans 2.0
More than test scores or good grades–what do kids need for the future? This hour, TED speakers explore how to help children grow into better humans, both during and after this time of crisis. Guests include educators Richard Culatta and Liz Kleinrock, psychologist Thomas Curran, and writer Jacqueline Woodson.
Now Playing: Science for the People

#556 The Power of Friendship
It's 2020 and times are tough. Maybe some of us are learning about social distancing the hard way. Maybe we just are all a little anxious. No matter what, we could probably use a friend. But what is a friend, exactly? And why do we need them so much? This week host Bethany Brookshire speaks with Lydia Denworth, author of the new book "Friendship: The Evolution, Biology, and Extraordinary Power of Life's Fundamental Bond". This episode is hosted by Bethany Brookshire, science writer from Science News.
Now Playing: Radiolab

Dispatch 3: Shared Immunity
More than a million people have caught Covid-19, and tens of thousands have died. But thousands more have survived and recovered. A week or so ago (aka, what feels like ten years in corona time) producer Molly Webster learned that many of those survivors possess a kind of superpower: antibodies trained to fight the virus. Not only that, they might be able to pass this power on to the people who are sick with corona, and still in the fight. Today we have the story of an experimental treatment that's popping up all over the country: convalescent plasma transfusion, a century-old procedure that some say may become one of our best weapons against this devastating, new disease.   If you have recovered from Covid-19 and want to donate plasma, national and local donation registries are gearing up to collect blood.  To sign up with the American Red Cross, a national organization that works in local communities, head here.  To find out more about the The National COVID-19 Convalescent Plasma Project, which we spoke about in our episode, including information on clinical trials or plasma donation projects in your community, go here.  And if you are in the greater New York City area, and want to donate convalescent plasma, head over to the New York Blood Center to sign up. Or, register with specific NYC hospitals here.   If you are sick with Covid-19, and are interested in participating in a clinical trial, or are looking for a plasma donor match, check in with your local hospital, university, or blood center for more; you can also find more information on trials at The National COVID-19 Convalescent Plasma Project. And lastly, Tatiana Prowell's tweet that tipped us off is here. This episode was reported by Molly Webster and produced by Pat Walters. Special thanks to Drs. Evan Bloch and Tim Byun, as well as the Albert Einstein College of Medicine.  Support Radiolab today at